Podcast: redefining breast cancer, tiny brain tumours, bowel cancer progress and more

Podcast logo

Click on the logo to download the podcast

This month, we hear how a landmark study could revolutionise breast cancer treatment, and take a look at the growing evidence on aspirin and cancer.

We also hear how obesity may be driving rises in kidney and womb cancer rates, while smoking patterns of the past mean that lung cancer continue to rise in women.

Plus, scientists develop the first snap-shot of tiny brain tumours, and we talk to Stephanie Moore MBE about how treatment for bowel cancer has changed since her husband, footballer Bobby Moore, died from the disease.

Listen now through the player below:

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Or click here to download the podcast as an mp3.

Also, the podcast is available on iTunes to subscribe and download for free.

Alternatively, go to the podcast page on our website, where you can hear the show directly through our own Flash player and explore previous shows in the archive. And there’s also a full transcript of the podcast available here.

We hope you enjoy it – please do let us know what you think of the podcast in the comments below, or email us at podcast@cancer.org.uk.

Kat

News digest – bowel cancer, kidney cancer, booze, boost for drug development, and more

Newspapers

All the news in one place

Another week has flown by, and yet more interesting cancer research was in the news, both from our own scientists and from research groups around the world.

We’ve summarised the big stories of the week below.

Click on the links for full coverage.

There were a few big stats stories out this week:

  • On Monday, new analysis showed that nearly 10 per cent of bowel cancer patients die within a month of diagnosis. And of these, over half are over 80 years old, and six in 10 are diagnosed following an emergency admission to hospital. This suggests that the public, especially the elderly, may not be aware of bowel cancer’s warning signs.
  • Then yesterday, we released new figures showing that the number of kidney cancers diagnosed each year in Great Britain has risen over 9,000 for the first time. Experts think that obesity is one of the key factors behind this staggering 135 per cent rise over the past 35 years.

Continue reading

Podcast: cancer genes, kids smoking, shunning sunbeds, and spotting the signs

Podcast logo

Click on the logo to download the podcast

In this month’s podcast a landmark cancer study sheds light on tumour genes, and experts suggest that more breast cancer patients should have genetic tests.

New figures reveal worrying numbers of schoolchildren taking up smoking, and leading model agencies sign up to a no-sunbed policy.

Meanwhile, a new drug combo destroys pancreatic cancer in the lab, and our Delay Kills report shows that ignorance and fear are behind thousands of avoidable cancer deaths.

Listen now through the audio player below:

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Or click here to download the podcast as an mp3.

Also, the podcast is available on iTunes to subscribe and download for free.

Alternatively, go to the podcast page on our website, where you can hear the show directly through our own Flash player and explore previous shows in the archive. And there’s also a full transcript of the podcast available here.

We hope you enjoy it – please do let us know what you think of the podcast in the comments below, or email us at podcast@cancer.org.uk.

Kat

News digest – complex kidney tumours, smoking warning, HRT and more

News

Read our weekly summary below

Some weeks are busier than others, and the past seven days have been a whirlwind. Lots of fascinating cancer research has been covered in the media, including some important work by our own scientists.

We’ve summarised the week for you below. Click on the links for further information on any of the stories that catch your eye.

If you want to share anything on Twitter or Facebook, then hover over the right hand portion of each section for share options.

Continue reading

On the origin of tumours

Darwin's first sketch of an evolutionary tree, from 1837

Researchers now think tumours evolve in a Darwinian fashion

“Cancer starts when a single cell in our body starts dividing out of control.”

We repeat this statement so often it would be banal, were it not for its implications.

But after a single, initial, malignant cell division, what happens to the two resulting ‘daughter’ cells? Are they identical to their parents? And what about their daughters? And their daughters’ daughters?

And what about the offspring that split off and travel around the body? After all, it’s usually cancer’s tendency to spread that makes it dangerous, rather than the initial tumour itself. But why is it that advanced cancer is so hard to treat?

Today, a team of some of the UK’s most exciting young researchers, funded by Cancer Research UK, University College London Cancer Institute, the Medical Research Council and the Wellcome Trust, has published results of a three-year analysis of kidney cancer samples.

Sequencing billions of ‘letters’ of DNA, the researchers looked in unprecedented detail at the relatedness of different regions of patients’ tumours, and between the patients’ primary tumour and the more distant secondaries, or ‘metastases’.

Their findings are stark: whichever way they looked at the data, no two samples from the same patient were genetically identical – not even samples next to each other in the original tumour. And the secondaries were significantly different from their parent tumour.

Their findings are the most compelling evidence yet that, like populations of animals in an ecosystem, tumours adapt as they grow, obeying the fundamental evolutionary laws laid down by Charles Darwin over a century ago. It seems this evolutionary aptitude may foster their ability to spread, and to become resistant to almost every treatment we can throw at them.

This heterogeneous nature of cancer has big implications for the way we think about the disease, and for how we continue to improve the way we treat it.

Continue reading

Shutting down cells’ ‘back-up generator’ to beat kidney cancer

A generator

Targeting cancer's back-up generator could help treat the disease

As well as the ingenuity, dedication and skill of their staff, modern hospitals can’t function properly without a reliable electricity supply. This is so critical that hospitals have a back-up generator to keep their life-saving systems working in an emergency..

In a similar way, our cells also have their own emergency back-up systems. Thanks to years of painstaking research, we now know that our cells have evolved multiple sets of similar internal machinery to carry out key processes like repairing DNA, generating energy, and sensing signals from the outside world.

This redundancy may seem wasteful, but it’s actually extremely important – it’s the key to life’s adaptability, allowing cells to take repeated knocks and yet still keep ticking over in changing and challenging circumstances.

But these vital fail-safe mechanisms come with a heavy price. As well as keeping healthy cells going during hard times, they also provide cancers with a path to invincibility. Tumour cells exploit these ‘back-up’ systems, becoming grossly abnormal while still carrying on dividing, shrugging off even the harshest of cancer treatments.

Thankfully, researchers are discovering how to target cancer cells that have become dependent on their reserve systems. This concept – dubbed ‘synthetic lethality’ – is a hot topic in the search for better cancer treatments. The term may sound familiar to regular blog readers as we’ve written about it several times before

This week, researchers at our Beatson Institute in Glasgow – working in collaboration with scientists in the US, Israel and Australia – have published a paper in the journal Nature  that could lead to new ways to treat kidney cancer, a disease that seldom gets much publicity despite affecting nearly 9,000 people a year in the UK.

Let’s take a look at the new study, and how it fits into an emerging success story in cancer research.

Continue reading

Kidney cancer drug access – the end of the story?

A kidney

NICE have decided not to approve three drugs to treat advanced kidney cancr

In April we wrote about the decision by the National Institute of Health and Clinical Excellence (NICE) not to recommend three new treatments for advanced kidney cancer on the NHS.

Today NICE have announced their final decision on these drugs.

As regular readers might remember, this time last year NICE ruled that none of four new drugs, bevacizumab (Avastin), sorafenib (Nexavar), temsirolimus (Torisel), or sunitinib (Sutent) should be recommended  to treat advanced kidney cancer on the NHS.

Since there are very few treatment options for people with advanced kidney cancer, we were naturally disappointed that NICE’s decision would mean that these new treatments, which have shown benefit in clinical trials, would not be routinely available on the NHS.

Sunitinib approved

In response to these concerns, in January NICE introduced new powers for its Committees, known as its ‘end of life’ criteria, and as a result, in February, sunitinib has now been successfully approved for use.

However, last night we found out that the appeal against NICE’s negative decision on the remaining three drugs has been unsuccessful. This decision is now final.

Continue reading